Conduit Strengthens Autoimmune Intellectual Property With New Patents For Lead Assets

Conduit Pharmaceuticals has filed four new patent applications, including its first ever for AZD5658, significantly expanding its intellectual property portfolio. The filings also cover new combinations involving AZD1656, Conduit’s other lead asset. These developments support the company’s strategy of advancing IP-rich, differentiated pharmaceutical assets, particularly in the autoimmune and inflammatory disease space.

"These filings are a strong validation of the progress we are making through our Sarborg partnership," said Dr. Joanne Holland, Chief Scientific Officer of Conduit Pharmaceuticals. "The depth and precision of the data outputs are helping us uncover untapped therapeutic combinations with meaningful commercial potential."

The patent filings stem from an ongoing AI-led collaboration with Sarborg Limited. This partnership has played a key role in identifying novel therapeutic combinations through extensive data analysis. The result is a growing library of patentable innovations with both strategic and commercial value.

Conduit will keep looking at further IP opportunities and will be talking to potential partners to license and develop. The company is also interested in a capital-efficient model that ensures maximum commercial exploitation of its growth portfolio, granted its robust intellectual property protection.